Skip to main content
SpringerLink
Log in
Book cover

Levodopa-Induced Dyskinesia in Parkinson's Disease pp 245–264Cite as

Cannabinoids and Levodopa-Induced Dyskinesia

  • Chapter
  • First Online:

Abstract

The endocannabinoid system modulates the release of excitatory and inhibitory neurotransmitters in several brain areas implicated in motor control. Cannabinoid and dopamine receptors are highly abundant and often co-expressed in the basal ganglia circuitry, and the cross talk between these two systems regulates short- and long-term synaptic plasticity in the striatum. Dysregulation of the endocannabinoid system has been reported in animal models of Parkinson’s disease and parkinsonian patients and is exacerbated in dyskinetic states, following chronic levodopa administration.

This chapter reviews recent investigations on the relationships between endocannabinoids and other neurotransmitter/neuromodulator systems in the basal ganglia, with the intent to underline their relevance for the pathophysiology of levodopa-induced dyskinesia and discuss new pharmacological approaches for their treatment.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–58.

    PubMed  CAS  Google Scholar 

  2. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22:1379–89.

    PubMed  Google Scholar 

  3. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190–9.

    PubMed  Google Scholar 

  4. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev. 2013;65:171–222.

    PubMed  CAS  Google Scholar 

  5. Verhagen Metman L, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50:1323–6.

    PubMed  CAS  Google Scholar 

  6. Del Dotto P, et al. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16:515–20.

    PubMed  Google Scholar 

  7. Sawada H, et al. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One. 2010;5:e15298.

    PubMed  PubMed Central  CAS  Google Scholar 

  8. Benarroch E. Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology. 2007;69:306–9.

    PubMed  Google Scholar 

  9. Morera-Herreras T, Miguelez C, Aristieta A, Ruiz-Ortega JA, Ugedo L. Endocannabinoid modulation of dopaminergic motor circuits. Front Pharmacol. 2012;3:110.

    PubMed  PubMed Central  Google Scholar 

  10. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389–462.

    PubMed  PubMed Central  CAS  Google Scholar 

  11. Chevaleyre V, Heifets BD, Kaeser PS, Sudhof TC, Castillo PE. Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron. 2007;54:801–12.

    PubMed  PubMed Central  CAS  Google Scholar 

  12. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309–80.

    PubMed  CAS  Google Scholar 

  13. O’Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol. 2007;152:576–82.

    PubMed  PubMed Central  Google Scholar 

  14. Lopez-Moreno JA, Gonzalez-Cuevas G, Moreno G, Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol. 2008;13:160–87.

    PubMed  CAS  Google Scholar 

  15. Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–9.

    PubMed  CAS  Google Scholar 

  16. Di Marzo V, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686–91.

    PubMed  Google Scholar 

  17. Mechoulam R, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83–90.

    PubMed  CAS  Google Scholar 

  18. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci. 1996;16:3934–42.

    PubMed  CAS  Google Scholar 

  19. Sugiura T, et al. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Biochem Biophys Res Commun. 1996;218:113–7.

    PubMed  CAS  Google Scholar 

  20. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem. 2006;281:26465–72.

    PubMed  CAS  Google Scholar 

  21. Bisogno T, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  22. Basavarajappa BS. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol. 2007;5:81–97.

    PubMed  PubMed Central  CAS  Google Scholar 

  23. Carrier EJ, et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004;65:999–1007.

    PubMed  CAS  Google Scholar 

  24. Sugiura T, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89–97.

    PubMed  CAS  Google Scholar 

  25. Beltramo M, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277:1094–7.

    PubMed  CAS  Google Scholar 

  26. Cravatt BF, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83–7.

    PubMed  CAS  Google Scholar 

  27. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006;281:36569–78.

    PubMed  CAS  Google Scholar 

  28. Giuffrida A, McMahon LR. In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson’s disease and abuse liability. Prostaglandins Other Lipid Mediat. 2010;91:90–103.

    PubMed  PubMed Central  CAS  Google Scholar 

  29. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol. 2003;140:802–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  30. Hampson AJ, et al. Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta. 1995;1259:173–9.

    PubMed  Google Scholar 

  31. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 1997;272:21181–6.

    PubMed  CAS  Google Scholar 

  32. Kim J, Alger BE. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci. 2004;7:697–8.

    PubMed  CAS  Google Scholar 

  33. Fowler CJ. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol. 2007;152:594–601.

    PubMed  PubMed Central  CAS  Google Scholar 

  34. Vila M, et al. The role of glial cells in Parkinson’s disease. Curr Opin Neurol. 2001;14:483–9.

    PubMed  CAS  Google Scholar 

  35. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 1998;422:69–73.

    PubMed  CAS  Google Scholar 

  36. Kozak KR, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277:44877–85.

    PubMed  CAS  Google Scholar 

  37. Dinh TP, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99:10819–24.

    PubMed  PubMed Central  CAS  Google Scholar 

  38. Justinova Z, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry. 2008;64:930–7.

    PubMed  PubMed Central  CAS  Google Scholar 

  39. Maccarrone M, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci. 2008;11:152–9.

    PubMed  CAS  Google Scholar 

  40. Kathuria S, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9:76–81.

    PubMed  CAS  Google Scholar 

  41. Gobbi G, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A. 2005;102:18620–5.

    PubMed  PubMed Central  CAS  Google Scholar 

  42. Maione S, et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther. 2006;316:969–82.

    PubMed  CAS  Google Scholar 

  43. Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol. 2010;13:373–86.

    PubMed  CAS  Google Scholar 

  44. Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:4–15.

    PubMed  PubMed Central  CAS  Google Scholar 

  45. Begg M, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005;106:133–45.

    PubMed  CAS  Google Scholar 

  46. Sharir H, et al. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol. 2012;7:856–65.

    PubMed  PubMed Central  Google Scholar 

  47. Henstridge CM, et al. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol. 2011;25:1835–48.

    PubMed  CAS  Google Scholar 

  48. Johns DG, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol. 2007;152:825–31.

    PubMed  PubMed Central  CAS  Google Scholar 

  49. McHugh D, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010;11:44.

    PubMed  PubMed Central  Google Scholar 

  50. Yin H, et al. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem. 2009;284:12328–38.

    PubMed  PubMed Central  CAS  Google Scholar 

  51. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299–318.

    PubMed  CAS  Google Scholar 

  52. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006;8:E298–306.

    PubMed  PubMed Central  Google Scholar 

  53. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004;141:775–85.

    PubMed  PubMed Central  CAS  Google Scholar 

  54. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;25:1904–13.

    PubMed  CAS  Google Scholar 

  55. Van Sickle MD, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329–32.

    PubMed  Google Scholar 

  56. Gong JP, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006;1071:10–23.

    PubMed  CAS  Google Scholar 

  57. Suarez J, et al. Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. Hippocampus. 2009;19:623–32.

    PubMed  CAS  Google Scholar 

  58. Onaivi ES, Ishiguro H, Gu S, Liu QR. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol. 2012;26:92–103.

    PubMed  PubMed Central  CAS  Google Scholar 

  59. Benito C, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci. 2003;23:11136–41.

    PubMed  CAS  Google Scholar 

  60. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005;95:437–45.

    PubMed  CAS  Google Scholar 

  61. Price DA, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci. 2009;29:2177–86.

    PubMed  PubMed Central  Google Scholar 

  62. Palazuelos J, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain. 2009;132:3152–64.

    PubMed  Google Scholar 

  63. Wallmichrath I, Szabo B. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience. 2002;113:671–82.

    PubMed  CAS  Google Scholar 

  64. Martin AB, et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology. 2008;33:1667–79.

    PubMed  CAS  Google Scholar 

  65. Fusco FR, et al. Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. Synapse. 2004;53:159–67.

    PubMed  CAS  Google Scholar 

  66. Uchigashima M, et al. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci. 2007;27:3663–76.

    PubMed  CAS  Google Scholar 

  67. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol. 2001;85:468–71.

    PubMed  CAS  Google Scholar 

  68. Morera-Herreras T, Ruiz-Ortega JA, Gomez-Urquijo S, Ugedo L. Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons. Neuroscience. 2008;151:817–23.

    PubMed  CAS  Google Scholar 

  69. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience. 2002;109:451–60.

    PubMed  CAS  Google Scholar 

  70. Haring M, Marsicano G, Lutz B, Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience. 2007;146:1212–9.

    PubMed  CAS  Google Scholar 

  71. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci. 2002;5:446–51.

    PubMed  CAS  Google Scholar 

  72. Sidlo Z, Reggio PH, Rice ME. Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels. Neurochem Int. 2008;52:80–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  73. Mathur BN, Lovinger DM. Endocannabinoid-dopamine interactions in striatal synaptic plasticity. Front Pharmacol. 2012;3:66.

    PubMed  PubMed Central  Google Scholar 

  74. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci. 1997;17:5327–33.

    PubMed  CAS  Google Scholar 

  75. Mukhopadhyay S, Howlett AC. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol. 2005;67:2016–24.

    PubMed  CAS  Google Scholar 

  76. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol. 2005;67:1697–704.

    PubMed  CAS  Google Scholar 

  77. Hojo M, et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci. 2008;108:308–19.

    PubMed  CAS  Google Scholar 

  78. Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci. 2008;30:79–84.

    Google Scholar 

  79. Caterina MJ, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816–24.

    PubMed  CAS  Google Scholar 

  80. Mezey E, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A. 2000;97:3655–60.

    PubMed  PubMed Central  CAS  Google Scholar 

  81. Micale V, et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology. 2009;34:593–606.

    PubMed  CAS  Google Scholar 

  82. Cristino L, et al. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 2006;139:1405–15.

    PubMed  CAS  Google Scholar 

  83. Szolcsanyi J. Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol Sci. 2000;21:41–2.

    PubMed  CAS  Google Scholar 

  84. Zygmunt PM, Julius I, Di Marzo I, Hogestatt ED. Anandamide – the other side of the coin. Trends Pharmacol Sci. 2000;21:43–4.

    PubMed  CAS  Google Scholar 

  85. De Petrocellis L, et al. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem. 2001;276:12856–63.

    PubMed  Google Scholar 

  86. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther. 2007;114:13–33.

    PubMed  CAS  Google Scholar 

  87. Sun Y, Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res. 2007;2007:23513.

    PubMed  PubMed Central  Google Scholar 

  88. Sun Y, et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 2007;152:734–43.

    PubMed  PubMed Central  CAS  Google Scholar 

  89. Bouaboula M, et al. Anandamide induced PPARgamma transcriptional activation and 3 T3-L1 preadipocyte differentiation. Eur J Pharmacol. 2005;517:174–81.

    PubMed  CAS  Google Scholar 

  90. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 2004;123:131–45.

    PubMed  CAS  Google Scholar 

  91. Cimini A, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience. 2005;130:325–37.

    PubMed  CAS  Google Scholar 

  92. Carta AR, et al. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson’s disease model. Neuroscience. 2011;194:250–61.

    PubMed  CAS  Google Scholar 

  93. Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP. Delta(9)-tetrahydrocannabinol (Delta(9)-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson’s disease. Neuropathol Appl Neurobiol. 2012;38:535–47.

    PubMed  CAS  Google Scholar 

  94. Swanson CR, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation. 2011;8:91.

    PubMed  PubMed Central  CAS  Google Scholar 

  95. Galan-Rodriguez B, et al. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology. 2009;56:653–64.

    PubMed  CAS  Google Scholar 

  96. Xiang GQ, et al. PPARgamma agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol. 2012;64:589–96.

    PubMed  CAS  Google Scholar 

  97. Dhikav V, Anand K. Potential predictors of hippocampal atrophy in Alzheimer’s disease. Drugs Aging. 2011;28:1–11.

    PubMed  CAS  Google Scholar 

  98. Medhi B, Aggarwal R, Chakrabarti A. Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. Indian J Exp Biol. 2010;48:793–9.

    PubMed  CAS  Google Scholar 

  99. Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett. 2005;388:7–12.

    PubMed  CAS  Google Scholar 

  100. Thal SC, et al. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-gamma-independent mechanisms. J Neurotrauma. 2011;28:983–93.

    PubMed  Google Scholar 

  101. Grover S, Kumar P, Singh K, Vikram V, Budhiraja RD. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)–alpha and gamma agonist against a rat model of oral dyskinesia. Pharmacol Biochem Behav. 2013;111:17–23.

    PubMed  CAS  Google Scholar 

  102. Compton DR, Martin BR. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther. 1997;283:1138–43.

    PubMed  CAS  Google Scholar 

  103. Morgese MG, Cassano T, Cuomo V, Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson’s disease: role of CB(1) and TRPV1 receptors. Exp Neurol. 2007;208:110–9.

    PubMed  PubMed Central  CAS  Google Scholar 

  104. Giuffrida A, Seillier A. New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:51–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  105. Ledent C, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401–4.

    PubMed  CAS  Google Scholar 

  106. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96:5780–5.

    PubMed  PubMed Central  CAS  Google Scholar 

  107. Li X, et al. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl). 2009;204:1–11.

    CAS  Google Scholar 

  108. McMahon LR, Koek W. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6 J mice. Eur J Pharmacol. 2007;569:70–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  109. Tzavara ET, et al. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry. 2006;59:508–15.

    PubMed  CAS  Google Scholar 

  110. Marinelli S, et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci. 2003;23:3136–44.

    PubMed  CAS  Google Scholar 

  111. Romero J, et al. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci. 2000;66:485–94.

    PubMed  CAS  Google Scholar 

  112. Lastres-Becker I, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson’s syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2001;14:1827–32.

    PubMed  CAS  Google Scholar 

  113. Van Laere K, et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson’s disease in vivo. Neurobiol Aging. 2012;33(620):e621–8.

    Google Scholar 

  114. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J. 2000;14:1432–8.

    PubMed  Google Scholar 

  115. Gubellini P, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci. 2002;22:6900–7.

    PubMed  CAS  Google Scholar 

  116. Maccarrone M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem. 2003;85:1018–25.

    PubMed  CAS  Google Scholar 

  117. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci. 2003;18:1607–14.

    PubMed  Google Scholar 

  118. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature. 2007;445:643–7.

    PubMed  CAS  Google Scholar 

  119. Zeng BY, et al. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett. 1999;276:71–4.

    PubMed  CAS  Google Scholar 

  120. Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol. 2001;47:60–8.

    Google Scholar 

  121. Picconi B, et al. Pathological synaptic plasticity in the striatum: implications for Parkinson’s disease. Neurotoxicology. 2005;26:779–83.

    PubMed  CAS  Google Scholar 

  122. Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl). 2001;156:79–85.

    CAS  Google Scholar 

  123. Fernandez-Espejo E, et al. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with severe nigral lesion in experimental parkinsonism. Neurobiol Dis. 2005;18:591–601.

    PubMed  CAS  Google Scholar 

  124. Kelsey JE, Harris O, Cassin J. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson’s disease. Behav Brain Res. 2009;203:304–7.

    PubMed  CAS  Google Scholar 

  125. van der Stelt M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease. FASEB J. 2005;19:1140–2.

    PubMed  Google Scholar 

  126. van Vliet SA, Vanwersch RA, Jongsma MJ, Olivier B, Philippens IH. Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model. Eur Neuropsychopharmacol. 2008;18:383–9.

    PubMed  Google Scholar 

  127. Carroll CB, et al. Cannabis for dyskinesia in Parkinson disease. Neurology. 2004;63:1245–50.

    PubMed  CAS  Google Scholar 

  128. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease. Mov Disord. 2002;17:1180–7.

    PubMed  Google Scholar 

  129. Sieradzan KA, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology. 2001;57:2108–11.

    PubMed  CAS  Google Scholar 

  130. Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson’s disease. Mov Disord. 2003;18:138–49.

    PubMed  Google Scholar 

  131. Martinez A, Macheda T, Morgese MG, Trabace L, Giuffrida A. The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci Res. 2012;72:236–42.

    PubMed  CAS  Google Scholar 

  132. Walsh S, Gorman AM, Finn DP, Dowd E. The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. Brain Res. 2010;1363:40–8.

    PubMed  CAS  Google Scholar 

  133. Mesnage V, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol. 2004;27:108–10.

    PubMed  CAS  Google Scholar 

  134. Cao X, et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther. 2007;323:318–26.

    PubMed  CAS  Google Scholar 

  135. Gonzalez-Aparicio R, Moratalla R. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson s disease. Neurobiol Dis. 2013;62C:416–25.

    Google Scholar 

  136. Giuffrida A, et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999;2:358–63.

    PubMed  CAS  Google Scholar 

  137. Masserano JM, Karoum F, Wyatt RJ. SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol. 1999;10:429–32.

    PubMed  CAS  Google Scholar 

  138. Bido S, Marti M, Morari M. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem. 2011;118:1043–55.

    PubMed  CAS  Google Scholar 

  139. Dupre KB, et al. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol. 2011;229:288–99.

    PubMed  PubMed Central  CAS  Google Scholar 

  140. Perez-Rial S, et al. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol Aging. 2011;32:631–45.

    PubMed  CAS  Google Scholar 

  141. Van Laere K. In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans. Eur J Nucl Med Mol Imaging. 2007;34:1719–26.

    PubMed  Google Scholar 

  142. Vitale C, et al. Unawareness of dyskinesias in Parkinson’s and Huntington’s diseases. Neurol Sci. 2001;22:105–6.

    PubMed  CAS  Google Scholar 

  143. Lee J, Di Marzo V, Brotchie JM. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology. 2006;51:557–65.

    PubMed  CAS  Google Scholar 

  144. Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci. 2002;3:574–9.

    PubMed  CAS  Google Scholar 

  145. Matyas F, et al. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience. 2006;137:337–61.

    PubMed  CAS  Google Scholar 

  146. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience. 2000;97:89–97.

    PubMed  CAS  Google Scholar 

  147. Julian MD, et al. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience. 2003;119:309–18.

    PubMed  CAS  Google Scholar 

  148. Malone DT, Taylor DA. Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol. 1999;128:21–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  149. Szabo B, Muller T, Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem. 1999;73:1084–9.

    PubMed  CAS  Google Scholar 

  150. Kofalvi A, et al. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci. 2005;25:2874–84.

    PubMed  Google Scholar 

  151. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernandez-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. 2004;1007:152–9.

    PubMed  Google Scholar 

  152. Marinelli S, et al. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology. 2007;32:298–308.

    PubMed  CAS  Google Scholar 

  153. Melis M, et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci. 2008;28:13985–94.

    PubMed  PubMed Central  CAS  Google Scholar 

  154. Patel S, Rademacher DJ, Hillard CJ. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther. 2003;306:880–8.

    PubMed  CAS  Google Scholar 

  155. Centonze D, et al. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission. Neuropsychopharmacology. 2004;29:1488–97.

    PubMed  CAS  Google Scholar 

  156. Andre VM, et al. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci. 2010;31:14–28.

    PubMed  Google Scholar 

  157. Tang K, Low MJ, Grandy DK, Lovinger DM. Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci U S A. 2001;98:1255–60.

    PubMed  PubMed Central  CAS  Google Scholar 

  158. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science. 2008;321:848–51.

    PubMed  PubMed Central  CAS  Google Scholar 

  159. Ade KK, Lovinger DM. Anandamide regulates postnatal development of long-term synaptic plasticity in the rat dorsolateral striatum. J Neurosci. 2007;27:2403–9.

    PubMed  CAS  Google Scholar 

  160. Adermark L, Lovinger DM. Frequency-dependent inversion of net striatal output by endocannabinoid-dependent plasticity at different synaptic inputs. J Neurosci. 2009;29:1375–80.

    PubMed  PubMed Central  CAS  Google Scholar 

  161. Lerner TN, Kreitzer AC. RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron. 2012;73:347–59.

    PubMed  PubMed Central  CAS  Google Scholar 

  162. Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 1998;85:395–403.

    PubMed  CAS  Google Scholar 

  163. Narushima M, Uchigashima M, Hashimoto K, Watanabe M, Kano M. Depolarization-induced suppression of inhibition mediated by endocannabinoids at synapses from fast-spiking interneurons to medium spiny neurons in the striatum. Eur J Neurosci. 2006;24:2246–52.

    PubMed  Google Scholar 

  164. Adermark L, Talani G, Lovinger DM. Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci. 2009;29:32–41.

    PubMed  PubMed Central  Google Scholar 

  165. Kreitzer AC, Malenka RC. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci. 2005;25:10537–45.

    PubMed  CAS  Google Scholar 

  166. Wang Z, et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron. 2006;50:443–52.

    PubMed  CAS  Google Scholar 

  167. Picconi B, et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain. 2011;134:375–87.

    PubMed  Google Scholar 

  168. Beltramo M, et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci. 2000;20:3401–7.

    PubMed  CAS  Google Scholar 

  169. Tozzi A, et al. The distinct role of medium spiny neurons and cholinergic interneurons in the D/AA receptor interaction in the striatum: implications for Parkinson’s disease. J Neurosci. 2011;31:1850–62.

    PubMed  CAS  Google Scholar 

  170. Martire A, et al. Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J Neurochem. 2011;116:273–80.

    PubMed  CAS  Google Scholar 

  171. Quiroz C, et al. Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal. 2009;9:1321–44.

    PubMed  PubMed Central  CAS  Google Scholar 

  172. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130:1819–33.

    PubMed  Google Scholar 

  173. Abdallah L, et al. Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. J Neurosci. 2009;29:8156–65.

    PubMed  PubMed Central  CAS  Google Scholar 

  174. Mathur BN, Capik NA, Alvarez VA, Lovinger DM. Serotonin induces long-term depression at corticostriatal synapses. J Neurosci. 2011;31:7402–11.

    PubMed  PubMed Central  CAS  Google Scholar 

  175. Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:19–24.

    PubMed  CAS  Google Scholar 

  176. Haring M, Grieb M, Monory K, Lutz B, Moreira FA. Cannabinoid CB(1) receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations. Neuropharmacology. 2013;65:83–9.

    PubMed  CAS  Google Scholar 

  177. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577–88.

    PubMed  CAS  Google Scholar 

  178. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64:20–4.

    PubMed  Google Scholar 

  179. Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM. New insights into the organization of the basal ganglia. Curr Neurol Neurosci Rep. 2009;9:298–304.

    PubMed  Google Scholar 

  180. Pifl C, Reither H, Hornykiewicz O. Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat. Brain Res. 1992;572:87–93. doi:0006-8993(92)90455-I [pii].

    PubMed  CAS  Google Scholar 

  181. Corvol JC, et al. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci. 2004;24:7007–14.

    PubMed  CAS  Google Scholar 

  182. Aubert I, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol. 2005;57:17–26.

    PubMed  CAS  Google Scholar 

  183. Oh JD, Del Dotto P, Chase TN. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett. 1997;228:5–8.

    PubMed  CAS  Google Scholar 

  184. Santini E, Valjent E, Fisone G. Parkinson’s disease: levodopa-induced dyskinesia and signal transduction. FEBS J. 2008;275:1392–9.

    PubMed  CAS  Google Scholar 

  185. Lebel M, Chagniel L, Bureau G, Cyr M. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis. 2010;38:59–67.

    PubMed  CAS  Google Scholar 

  186. Santini E, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27:6995–7005.

    PubMed  CAS  Google Scholar 

  187. Cyr M, et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A. 2003;100:11035–40.

    PubMed  PubMed Central  CAS  Google Scholar 

  188. Hemmings Jr HC, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984;310:503–5.

    PubMed  CAS  Google Scholar 

  189. Andersson M, et al. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci. 2005;25:8432–8.

    PubMed  CAS  Google Scholar 

  190. Polissidis A, et al. Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol. 2010;13:1175–91.

    PubMed  CAS  Google Scholar 

  191. Carta AR. PPAR-gamma: therapeutic prospects in Parkinson’s disease. Curr Drug Targets. 2013;14:743–51.

    PubMed  CAS  Google Scholar 

Download references

Funding Sources

NS 050401–07 and M.J. Fox Foundation (to A.G.); 1F31NS073411-03 (to A.M.)

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA

    Andrea Giuffrida & Alex Martinez

  2. Department of Biology, Trinity University, San Antonio, TX, USA

    Alex Martinez

Authors
  1. Andrea Giuffrida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Giuffrida .

Editor information

Editors and Affiliations

  1. Toronto Western Hospital, Toronto, Ontario, Canada

    Susan H. Fox

  2. Toronto Western Hospital, Toronto, Ontario, Canada

    Jonathan M. Brotchie

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Giuffrida, A., Martinez, A. (2014). Cannabinoids and Levodopa-Induced Dyskinesia. In: Fox, S., Brotchie, J. (eds) Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer, London. https://doi.org/10.1007/978-1-4471-6503-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6503-3_14

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6502-6

  • Online ISBN: 978-1-4471-6503-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation